Glaucoma Biomarkers

Exclusion Criteria

• •Contact lenses removed prior to topical fluorescein instillation, and not used until the end of each fluorophotometry session.
• •Able to participate on site over the multi-visit study period.
• •Women who are pregnant due to IOP changes.
• •Any form of glaucoma, including extremely narrow angle with complete or partial closure.
• •Current use of any glaucoma medication, either topically or orally.
• •Chronic or recurrent inflammatory eye disease.
• •Ocular trauma within the past 6 months.
• •Ocular infection or ocular inflammation in the past 3 months.
• •Clinically significant retinal disease.
• •Any abnormality preventing reliable fluorophotometry of either eye, such as corneal scarring or severe dry eye that results in punctate fluorescein staining of the cornea.
• •Intraocular surgery within 6 months.
• •Serious hypersensitivity to any components of the study medications or risk from treatment with glaucoma medications, such as severe asthma or emphysema.
• •Subjects must be on a stable regimen for at least 30 days prior to the Visit 1 regarding a chronic systemic medication that may affect IOP (i.e., sympathomimetic agents, beta-blockers, alpha-adrenergic agonists, alpha-adrenergic blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, etc.). Any change of such medication during the study period will result in exclusion.
• •Use of any glucocorticoid by any route. Subject must be washed out of the glucocorticoid for at least 2 weeks before study entry.